Why the study?
Ewing sarcomas are uncommon malignant neoplasms requiring accurate differential diagnosis, where immunohistochemistry serves as an important diagnostic tool alongside conventional techniques.
What is the sensitivity of CD99 and PAX8 immunohistochemistry in molecularly confirmed Ewing Sarcoma?
What is the sensitivity of CD99 and PAX8 immunohistochemistry in molecularly confirmed Ewing Sarcoma?
CD99 and PAX8 show high sensitivity in Ewing Sarcoma, but due to expression in other tumors, molecular confirmation remains necessary.
May support CD99/PAX8 IHC adjuncts in Ewing sarcoma; leaves open specificity and generalizability pending larger validation.
Ewing sarcomas are an uncommon group of malignant neoplasms. A multidisciplinary approach is highly recommended to reach a correct diagnosis, considering the clinical, radiological, and histopathological aspects. Since in up to 90% of cases, the translocation t (11; 22) (q24; q12) occurs resulting in a chimeric fusion transcript EWSR1-FLI-1. The pathologist has several tools in addition to conventional techniques (hematoxylin and eosin), such as immunohistochemistry, which plays a very important role in the differential diagnosis. We present a series of 15 cases of molecularly confirmed ES, in which we found a sensitivity of 100% for CD99 and 80% for PAX8 by immunohistochemistry. This indicates a high sensitivity; however, it is known that both CD99 and PAX8 are also expressed in other tumours. Therefore, molecular confirmation should be performed in all cases.
No takes yet. Share an insight, caveat, or question.
Chinchilla-Tábora et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: